An Effectiveness Evaluation for Pathway to Healthy Aging (Path-HA) Care on Health Status of Older Adults
Launched by THE UNIVERSITY OF HONG KONG · Oct 23, 2023
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Pathway to Healthy Aging (Path-HA) clinical trial is studying how a special program can help improve the health and daily functioning of older adults who may be experiencing signs of faster aging. The program lasts for 14 weeks and aims to enhance the quality of life for participants by addressing factors like physical activity, nutrition, and mental well-being. In this trial, older adults aged 60 and above, who have at least two risk factors for accelerated aging—such as trouble moving, feelings of loneliness, or sleep issues—are invited to participate.
Participants will be randomly assigned to either receive the Path-HA care program or be part of a control group that does not receive the program. Those who take part can expect to engage in health education activities designed to support their well-being. This trial is currently recruiting, and it’s open to all genders, focusing on community-dwelling individuals who can communicate effectively with the research team. If you or a loved one meets the eligibility criteria, this could be an opportunity to gain valuable support in aging healthily.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) aged 60 or above,
- • 2) with at least two risk factors of accelerating aging defined as including reduced physical functioning, malnutrition, depressed mood, loneliness, poor health perception, and presence of geriatric symptoms (e.g. insomnia, pain, etc), based on their health screening results,
- • 3) community-dwelling,
- • 4) communicable to engage in health education activity.
- Exclusion Criteria:
- • 1) any who is not at or at only one risk factor of accelerating aging,
- • 2) any who has problems in communicating with the research team.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Doris Sau Fung YU, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported